CN103520120A - 一种替比培南匹伏酯组合物颗粒剂 - Google Patents
一种替比培南匹伏酯组合物颗粒剂 Download PDFInfo
- Publication number
- CN103520120A CN103520120A CN201310493646.3A CN201310493646A CN103520120A CN 103520120 A CN103520120 A CN 103520120A CN 201310493646 A CN201310493646 A CN 201310493646A CN 103520120 A CN103520120 A CN 103520120A
- Authority
- CN
- China
- Prior art keywords
- composition granule
- granule
- present
- tebipenam
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 229950009297 pivoxil Drugs 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 229920000881 Modified starch Polymers 0.000 claims abstract description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 10
- 229930006000 Sucrose Natural products 0.000 claims abstract description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 9
- 229930195725 Mannitol Natural products 0.000 claims abstract description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 9
- 239000000594 mannitol Substances 0.000 claims abstract description 9
- 235000010355 mannitol Nutrition 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 235000019202 steviosides Nutrition 0.000 claims abstract description 9
- 229940013618 stevioside Drugs 0.000 claims abstract description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000005720 sucrose Substances 0.000 claims description 9
- 238000007908 dry granulation Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- 238000004090 dissolution Methods 0.000 abstract description 10
- 229920000642 polymer Polymers 0.000 abstract description 6
- 239000012535 impurity Substances 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 27
- 239000000126 substance Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- SNUDIPVBUUXCDG-QHSBEEBCSA-N tebipenem pivoxil Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 SNUDIPVBUUXCDG-QHSBEEBCSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008019 pharmaceutical lubricant Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 229940095686 granule product Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310493646.3A CN103520120B (zh) | 2013-10-17 | 2013-10-17 | 一种替比培南匹伏酯组合物颗粒剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310493646.3A CN103520120B (zh) | 2013-10-17 | 2013-10-17 | 一种替比培南匹伏酯组合物颗粒剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103520120A true CN103520120A (zh) | 2014-01-22 |
CN103520120B CN103520120B (zh) | 2015-07-29 |
Family
ID=49922711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310493646.3A Active CN103520120B (zh) | 2013-10-17 | 2013-10-17 | 一种替比培南匹伏酯组合物颗粒剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103520120B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104055739A (zh) * | 2014-07-07 | 2014-09-24 | 山东罗欣药业集团股份有限公司 | 一种替比培南匹伏酯组合物颗粒剂的制备方法 |
CN104224733A (zh) * | 2014-09-30 | 2014-12-24 | 蔡伦 | 一种氯雷他定颗粒剂及其制备方法 |
CN107737107A (zh) * | 2017-12-02 | 2018-02-27 | 北京达因高科儿童药物研究院有限公司 | 一种含替比培南酯组合物的口服制剂及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004035517A (ja) * | 2002-07-08 | 2004-02-05 | Wyeth Lederle Japan Ltd | カルバペネム系抗生剤含有経口製剤 |
CN102824314A (zh) * | 2012-09-19 | 2012-12-19 | 山东罗欣药业股份有限公司 | 一种替比培南匹伏酯颗粒剂的制备方法 |
CN102836130A (zh) * | 2012-09-19 | 2012-12-26 | 山东罗欣药业股份有限公司 | 一种替比培南匹伏酯颗粒剂 |
CN102860985A (zh) * | 2011-07-06 | 2013-01-09 | 石药集团中奇制药技术(石家庄)有限公司 | 一种泰比培南酯口服制剂及其制备方法 |
CN103054815A (zh) * | 2013-02-04 | 2013-04-24 | 南京卡文迪许生物工程技术有限公司 | 替比培南酯口服固体制剂及其制备方法 |
-
2013
- 2013-10-17 CN CN201310493646.3A patent/CN103520120B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004035517A (ja) * | 2002-07-08 | 2004-02-05 | Wyeth Lederle Japan Ltd | カルバペネム系抗生剤含有経口製剤 |
CN102860985A (zh) * | 2011-07-06 | 2013-01-09 | 石药集团中奇制药技术(石家庄)有限公司 | 一种泰比培南酯口服制剂及其制备方法 |
CN102824314A (zh) * | 2012-09-19 | 2012-12-19 | 山东罗欣药业股份有限公司 | 一种替比培南匹伏酯颗粒剂的制备方法 |
CN102836130A (zh) * | 2012-09-19 | 2012-12-26 | 山东罗欣药业股份有限公司 | 一种替比培南匹伏酯颗粒剂 |
CN103054815A (zh) * | 2013-02-04 | 2013-04-24 | 南京卡文迪许生物工程技术有限公司 | 替比培南酯口服固体制剂及其制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104055739A (zh) * | 2014-07-07 | 2014-09-24 | 山东罗欣药业集团股份有限公司 | 一种替比培南匹伏酯组合物颗粒剂的制备方法 |
CN104224733A (zh) * | 2014-09-30 | 2014-12-24 | 蔡伦 | 一种氯雷他定颗粒剂及其制备方法 |
CN104224733B (zh) * | 2014-09-30 | 2016-08-17 | 蔡伦 | 一种氯雷他定颗粒剂及其制备方法 |
CN107737107A (zh) * | 2017-12-02 | 2018-02-27 | 北京达因高科儿童药物研究院有限公司 | 一种含替比培南酯组合物的口服制剂及其制备方法 |
CN107737107B (zh) * | 2017-12-02 | 2020-05-29 | 北京达因高科儿童药物研究院有限公司 | 一种含替比培南酯组合物的口服制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103520120B (zh) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520120B (zh) | 一种替比培南匹伏酯组合物颗粒剂 | |
CN103417512B (zh) | 一种阿莫西林胶囊剂及其制备方法 | |
CN103524532B (zh) | 一种头孢唑肟钠化合物晶型、制备方法及其药物制剂 | |
CN103371977A (zh) | 一种泰比培南酯颗粒及其制备方法 | |
CN103467494B (zh) | 一种头孢地尼的新晶型及其制备方法 | |
CN103622916B (zh) | 一种头孢克肟干混悬制剂及其制备方法 | |
CN104873501A (zh) | 一种治疗感染性疾病的舒巴坦钠组合物 | |
CN102836130A (zh) | 一种替比培南匹伏酯颗粒剂 | |
CN101904822B (zh) | 一种法罗培南钠冻干粉针及其制备方法 | |
CN104546735A (zh) | 一种小儿用甲苯磺酸妥舒沙星颗粒及其制备方法 | |
CN103284958B (zh) | 一种头孢地尼组合物颗粒剂及其制备方法 | |
CN104323984A (zh) | 一种瑞他莫林软膏药物组合物及其制备方法 | |
CN102344458B (zh) | 一种头孢丙烯化合物晶体及其药物组合物 | |
CN103304604B (zh) | 一种克林霉素磷酸酯化合物,其制备方法及其药物组合物 | |
CN103191062A (zh) | 一种磺苄西林钠的注射剂 | |
CN102311452A (zh) | 头孢克肟晶体、其制备方法及含有该晶体的片剂组合物 | |
CN103191061B (zh) | 一种注射用头孢拉宗钠组合物粉针及其制备方法 | |
CN102824314A (zh) | 一种替比培南匹伏酯颗粒剂的制备方法 | |
CN105496984A (zh) | 一种质量稳定的头孢克肟胶囊及其制备方法 | |
CN104382849B (zh) | 一种头孢克洛干混悬剂及其制备方法 | |
CN103622933B (zh) | 一种头孢地尼胶囊及其制备方法 | |
CN102232955B (zh) | 无定形头孢呋辛酯口服抗菌组合物的制备方法及其制备的组合物、复方制剂 | |
CN103110624A (zh) | 一种阿莫西林钠与克拉维酸钾的药物组合物 | |
CN104069072A (zh) | 一种替比培南匹伏酯组合物颗粒剂 | |
CN102250095A (zh) | 碳青霉烯衍生物或其水合物的晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. Effective date: 20150630 Owner name: SHANDONG YUXIN PHARMACEUTICAL CO., LTD. SHANDONG H Effective date: 20150630 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ji Honghai Inventor after: Sun Yiwei Inventor after: Ruan Xizhe Inventor after: Liu Mingxia Inventor after: Niu Hongfen Inventor after: Yang Lijuan Inventor before: Liu Mingxia Inventor before: Niu Hongfen Inventor before: Liu Wenwen Inventor before: Yang Lijuan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU MINGXIA NIU HONGFEN LIU WENWEN YANG LIJUAN TO: JI HONGHAI SUN YIWEI RUAN XIZHE LIU MINGXIA NIU HONGFEN YANG LIJUAN |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150630 Address after: Seven of 276017 Shandong province Linyi city Luozhuang District No. 18 Applicant after: Shandong Luo Xin Pharmaceutical Group Plc Applicant after: Shandong Yu Xin pharmaceutcal corporation, Ltd Applicant after: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. Address before: Seven of 276017 Shandong province Linyi city Luozhuang District No. 18 Applicant before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee after: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee after: Shandong Luoxin Pharmaceutical Group Hengxin Pharmacy Co., Ltd. Address before: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee before: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee before: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee before: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. |